Abstract:Abstract Background: The three highly structurally related TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) exert greatly different effects on cancer and immune cells under various physiological conditions. Efforts to target the TGF-β pathway have been hampered by systemic toxicity or limited efficacy due to challenges associated with the global inhibition of TGF-βs. Recently, TGF-β1 was proven to be a critical player in generating an immunosuppressive tumor microenvironment (TME). TGF-β1 is expressed as an inactive latent form (L-TGF-β1) and activated upon binding to integrins, and integrin αvβ8 is a key activator of TGF-β1 in TME. Here, an ADCC-enhanced αvβ8 blocking antibody, 2MW4991, was developed to specifically inhibit TGF-β1-mediated signaling for the treatment of αvβ8-expressing cancers. Methods: Binding ability, specificity, and affinity of antibodies were measured by Flow cytometry and Biacore T200. A blocking assay was performed using U251MG cells and TGF-β signaling reporter cells. Jurkat/h FcγRIIIa reporter system was used to assess the ADCC activity of 2MW4991. Mouse syngeneic tumor models were used to characterize the in vivo anti-tumor efficacy. A repeat dose administration study was performed in cynomolgus monkeys to evaluate the pharmacokinetic and toxicity profiles of 2MW4991. Results: ScRNA-seq analysis of kidney renal clear cell carcinoma (KIRC) and head and neck squamous cell carcinoma (HNSCC) clinical samples revealed that αvβ8 highly expresses in tumor and some myeloid-derived cells, suggesting the development of ADCC-enhanced αvβ8 blocking antibodies for the treatment of αvβ8-expressing cancers. 2MW4991 showed sub-nanomolar binding affinity and high specificity to αvβ8, with no cross-reactivity to other integrins. 2MW4991 could effectively block TGF-β1 release in a GARP/L-TGF-β1/αvβ8 reporter system. In an immune-excluded EMT6 syngeneic model, 2MW4991 promoted substantial tumor regression and reversed immune suppressive TME by significantly increasing tumor infiltration of CD8+ T and innate immune cells. As expected, TGF-β1 blockade significantly increased the sensitivity of anti-PD-1 therapy in a combination study. Furthermore, 2MW4991 displayed potent anti-tumor efficacy in the human αvβ8 knock-in syngeneic model mimicking αvβ8 expression in human cancers. In a repeat dose administration NHP study, 2MW4991 showed a good pharmacokinetic profile and was well tolerated at a high dose of 100 mg/kg, accompanied by significantly declined pharmacodynamic biomarker TGF-β1 in peripheral blood. Conclusion: Integrin αvβ8 is a main activator of TGF-β1 in the TME and overexpressed in some cancer types. 2MW4991 demonstrated potent anti-tumor activity by unleashing the immune cells suppressed by TGF-β1 in TME and Fc-mediated immune functions. These compelling preclinical results support further evaluation of 2MW4991 in clinical trials. Citation Format: Cuicui Guo, Zhen Han, Xiaowei Cen, Hai Wu, Jinchao Zhang, Xun Gui. 2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6349.

Aptamer BT200 blocks interaction of K1405-1408 in the VWF-A1 domain with macrophage LRP1

Abstract WP97: The Aptamer BT200 Blocks Von Willebrand Factor and Platelet Function in Blood of Stroke Patients

Experimental study of interaction between activated VWF and targeted lipid microbubbles conjugated with recombinant GPⅠba

Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans

Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module

R1205H (Vicenza) causes conformational changes in the von Willebrand factor D'D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI

In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody

Abstract 6349: 2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys

Alkylation of Phosphorothioated Thrombin Binding Aptamers Improves the Selectivity of Inhibition of Tumor Cell Proliferation Upon Anticoagulation.

Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact

Exploring ligands that target von Willebrand factor selectively under oxidizing conditions through docking and molecular dynamics simulations

Aptamer-based biotherapeutic conjugate for shear responsive release of Von Willebrand factor A1 domain

Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII

Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear

Artificial Base-Directed In Vivo Formulation of Aptamer–Drug Conjugates with Albumin for Long Circulation and Targeted Delivery

An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBD

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.